Listen to your elders: why biopharma should be looking to small molecule experts for guidance

It’s been a rapid journey for the biopharma industry over the last few years. We’ve seen the industry stagger to its feet – surpassing notable early setbacks caused by lack of control over hyperallergenic drugs, Rutger Oudejans, Brand Director, bioLIVE at UBM, observes in an Expert View article for The Pharma Letter.

But recent successes means biopharma is graduating. We’re seeing biopharmaceutical products succeed, with good efficacy rates, long-lasting reach and real patient impact. The pipeline is filled with next generation technologies.

In fact, the biopharma industry is predicted to grow at an unprecedented rate over the next few years, with a CAGR of 8.5% between 2017 and 2023. Biopharma is graduating at the top of the class. Stunned by the magnitude of its success, will biopharma fall and stumble in the adult world? Or will biotech leaders acknowledge that someone has grown up before them: the small molecule industry?